To compare the 12-hour efficacy and safety of dorzolamide/timolol fixed combination (DTFC) dosed twice daily versus latanoprost dosed every evening following a timolol run-in in primary open-angle glaucoma patients.
Methods
Following a 6-week timolol run-in patients were randomized to either DTFC or latanoprost for 6 weeks and then changed to the opposite treatment for 6 weeks. At the end of the run-in, and the end of each treatment period, the intraocular pressure (IOP) was measured every 2 hours between 8:00 AM and 8:00 PM.
Results
Thirty-one patients completed at least one time point in both treatment periods. Both treatments reduced the IOP for the diurnal curve, and at each time point, from the timolol run-in baseline (p<0.0001). The 12-hour IOP on timolol was 22.1±2.8 mmHg, whereas on DTFC it was 18.1±2.8 and latanoprost 18.3±3.1 mmHg (p=0.4). Further, there was no statistical difference in IOP between treatments at any time point (p≤0.1). There was no statistical difference for any individual adverse event between treatments (p>0.05).
Conclusions
This study suggests that following a timolol run-in both DTFC and latanoprost provide comparable daytime efficacy and safety.
StewartW.C., StewartJ.A., NelsonL.A., KruftB.Physician attitudes regarding prostaglandin treatment for glaucoma in the United States and Europe. Eur J Ophthalmol2008; 18: 199–204.
2.
AlmA., StjernschantzJ.Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology1995; 102: 1743–52.
3.
CamrasC.B.Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology1996; 103: 138–47.
4.
WatsonP., StjernschantzJ.A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology1996; 103: 126–37.
5.
SmithS.L., PruittC.A., SineC.S., HudginsA.C., StewartW.C.The use of latanoprost 0.005% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol Scand1999; 77: 189–92.
6.
ClineschmidtC.M., WilliamsR.D., SnyderE., AdamsonsI.A.A randomized trial in patients inadequately controlled on timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology1999; 106: 17–24.
7.
HutzelmannJ., OwensS., SheddenA., AdamsonsI., VargasE.Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol1998; 82: 1249–53.
8.
BoyleJ.E., GhoshK., GieserD.K., AdamsonsI.A.A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol or dorzolamide. Ophthalmology1999; 106(suppl): S10–6.
9.
FechtnerR.D., AiraksinenP.J., GetsonA.J., LinesC.R., AdamsonsI.A.COSOPT versus XALATAN Study Groups. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand2004; 82: 42–8.
10.
KonstasA.G., PapapanosP., TersisI., HouliaraD., StewartW.C.Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology2003; 110: 1357–60.
11.
OrzalesiN., RossettiL., BottoliA., FumagalliE., FogagnoloP.The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol2003; 121: 453–7.
12.
BookS.A.Essentials of Statistics. New York: McGraw Hill, 1978; 7: 222–46.
13.
MundorfT.K., CateE.A., SineC.S., OteroD.W., StewartJ.A., StewartW.C.The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. J Ocul Pharmacol Ther1998; 14: 129–35.
14.
DuffG.R.A double-masked crossover study comparing the effects of carteolol 1% and 2% on intraocular pressure. Acta Ophthalmol (Copenh)1987; 65: 618–21.
15.
StewartW.C., LelandT.M., CateE.A., StewartJ.A.Efficacy and safety of timolol solution once daily vs. timolol gel in treating elevated IOP. J Glaucoma1998; 7: 402–7.
16.
StewartW.C., SharpeE.D., HarbinT.S.Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce the intraocular pressure. Am J Ophthalmol2000; 129: 723–7.
NilssonS.F., SamuelssonM., BillA., StjernschantzJ.Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F-2-alfa-1-isopropilester in the cynomolgus monkey. Exp Eye Res1989; 48: 707–96.
19.
GabeltB.T., KaufmanP.L.Prostaglandin F2a increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res1989; 49: 389–402.
20.
KerstetterJ.R., BrubakerR.F., WilsonS.E., KullerstrandL.J.Prostaglandin F2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am J Ophthalmol1988; 105: 30–4.
21.
TorisC.B., CamrasC.B., YablonskiM.E.Effects of PhXA41, a new prostaglandin F2-alpha analogue, on aqueous humor dynamics in human eyes. Ophthalmology1993; 100: 1297–304.
22.
StewartW.C., DayD.G., StewartJ.A., SchuhrJ., LathamK.E.The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol2001; 131: 631–5.
23.
BayerA., WeilerW., OeverhausU., SkrotzkiF.E., StewartW.C.Xplore Observation Group. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. J Ocul Pharmacol Ther2004; 20: 470–8.
24.
KonstasA.G., KatsimbrisJ.M., LallosN., BoukarasG.P., JenkinsJ.N., StewartW.C.Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology2005; 112: 262–6.
25.
NetlandP.A., LandryT., SullivanE.K.Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol2001; 132: 472–84.
26.
ParrishR.K., PalmbergP., SheuW.P.XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol2003; 135: 688–703.
MoroiS.E., GottfredsdottirM.S., SchteingartM.T.Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology1999; 106: 1024–9.
30.
KaufmanH.E., VarnellE.D., ThompsonH.W.Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol1999; 127: 531–6.
31.
BrubakerR.F., IngramC.J., SchoffE.O., NauC.B.Comparison of the efficacy of betaxolol-brinzolamide and timolol-dorzolamide as suppressors of aqueous humor flow in human subjects. Ophthalmology2000; 107: 283–7.
32.
BogerW.P.3rd. Short term “escape” and long term “drift.” The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol1983; 28: 235–42.
33.
CamrasC.B., AlmA., WatsonP., StiernschantzJ., Latanoprost Study Groups. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology1996; 103: 1916–24.
34.
BoyleJ.E., GhoshK., GieserD.K., AdamsonsI.A., The Dorzolamide-Timolol Study Group. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology1998; 105: 1945–51.
35.
ClineschmidtC.M., WilliamsR.D., SnyderE., AdamsonsI.A., the Dorzolamide-Timolol Combination Study Group. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology1998; 105: 1952–9.
36.
KonstasA.G., KozobolisV.P., TsironiS., MakridakiI., EfremovaR., StewartW.C.Comparison of the 24-hour intraocular pressure lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. Ophthalmology2008; 115: 99–103.
